These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 9408018)

  • 1. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group.
    Aygören-Pürsün E; Scharrer I
    Thromb Haemost; 1997 Nov; 78(5):1352-6. PubMed ID: 9408018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A.
    Yoshioka A; Fukutake K; Takamatsu J; Shirahata A;
    Int J Hematol; 2003 Dec; 78(5):467-74. PubMed ID: 14704043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group.
    White GC; Courter S; Bray GL; Lee M; Gomperts ED
    Thromb Haemost; 1997 Apr; 77(4):660-7. PubMed ID: 9134639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A.
    Shirahata A; Fukutake K; Takamatsu J; Shima M; Yoshioka A
    Int J Hematol; 2000 Jul; 72(1):101-7. PubMed ID: 10979218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.
    Abshire TC; Brackmann HH; Scharrer I; Hoots K; Gazengel C; Powell JS; Gorina E; Kellermann E; Vosburgh E
    Thromb Haemost; 2000 Jun; 83(6):811-6. PubMed ID: 10896230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
    Musso R; Santagostino E; Faradji A; Iorio A; van der Meer J; Ingerslev J; Lambert T; Maas-Enriquez M; Gorina E;
    Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
    Musso R
    Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group.
    Seremetis S; Lusher JM; Abildgaard CF; Kasper CK; Allred R; Hurst D
    Haemophilia; 1999 Jan; 5(1):9-16. PubMed ID: 10215942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
    Fukui H; Yoshioka A; Shima M; Tanaka I; Koshihara K; Fukutake K; Fujimaki M
    Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China.
    Shi J; Zhao Y; Wu J; Sun J; Wang L; Yang R
    Haemophilia; 2007 Jul; 13(4):351-6. PubMed ID: 17610547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data.
    Yoshioka A; Fukutake K; Takamatsu J; Shirahata A;
    Int J Hematol; 2006 Aug; 84(2):158-65. PubMed ID: 16926139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation.
    Lusher J; Abildgaard C; Arkin S; Mannucci PM; Zimmermann R; Schwartz L; Hurst D
    J Thromb Haemost; 2004 Apr; 2(4):574-83. PubMed ID: 15102011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.
    Bray GL; Gomperts ED; Courter S; Gruppo R; Gordon EM; Manco-Johnson M; Shapiro A; Scheibel E; White G; Lee M
    Blood; 1994 May; 83(9):2428-35. PubMed ID: 8167332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inhibitor development against FVIII in previously treated patients with haemophilia A. A retrospective data collection].
    Siegmund B; Pollmann H; Richter H; Orlovic M; Gottstein S; Klamroth R
    Hamostaseologie; 2010 Nov; 30 Suppl 1():S37-9. PubMed ID: 21042673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
    Kim SK; Yoo KY; Lee KS; Hwang T; Choi YM; Choi EJ; Park SK
    J Korean Med Sci; 2018 Jan; 33(1):e5. PubMed ID: 29215814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation.
    Kreuz W; Gill JC; Rothschild C; Manco-Johnson MJ; Lusher JM; Kellermann E; Gorina E; Larson PJ;
    Thromb Haemost; 2005 Mar; 93(3):457-67. PubMed ID: 15735795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.
    Mahlangu J; Kuliczkowski K; Karim FA; Stasyshyn O; Kosinova MV; Lepatan LM; Skotnicki A; Boggio LN; Klamroth R; Oldenburg J; Hellmann A; Santagostino E; Baker RI; Fischer K; Gill JC; P'Ng S; Chowdary P; Escobar MA; Khayat CD; Rusen L; Bensen-Kennedy D; Blackman N; Limsakun T; Veldman A; St Ledger K; Pabinger I;
    Blood; 2016 Aug; 128(5):630-7. PubMed ID: 27330001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of treatment regimens, efficacy and safety of a recombinant factor VIII concentrate in haemophilia A: the German EffeKt study.
    Klamroth R; Miesbach W; Staritz P;
    Haemophilia; 2016 Sep; 22(5):684-91. PubMed ID: 27030540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
    Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
    Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.